Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.Eli Lilly and Novo Nordisk are two of the biggest names in healthcare thanks in large part to some promising weight-loss drugs in their respective portfolios. In the past 12 months, Eli Lilly has doubled in value, while Novo Nordisk's stock is up around 50%. Those who haven't invested in these stocks may be inclined to pass on them given their high valuations now -- both are worth more than $500 billion.There are other ways to invest i ...